Free Trial

Spear Holdings RSC Ltd Acquires Shares of 271,900 Danaher Corporation (NYSE:DHR)

Danaher logo with Medical background

Spear Holdings RSC Ltd purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 271,900 shares of the conglomerate's stock, valued at approximately $55,740,000. Danaher accounts for about 4.3% of Spear Holdings RSC Ltd's investment portfolio, making the stock its 8th largest position.

A number of other large investors also recently bought and sold shares of DHR. Fortis Capital Advisors LLC grew its position in shares of Danaher by 1.3% during the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after buying an additional 50 shares during the period. Fayez Sarofim & Co grew its position in shares of Danaher by 0.6% during the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after buying an additional 50 shares during the period. Coastal Bridge Advisors LLC grew its position in shares of Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after purchasing an additional 50 shares during the period. Perennial Investment Advisors LLC grew its position in shares of Danaher by 2.2% in the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after purchasing an additional 51 shares during the period. Finally, Sound View Wealth Advisors Group LLC grew its position in shares of Danaher by 3.1% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock valued at $399,000 after purchasing an additional 52 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insiders Place Their Bets

In related news, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president owned 15,179 shares in the company, valued at approximately $3,005,442. This represents a 51.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by corporate insiders.

Danaher Stock Down 1.8%

Shares of Danaher stock traded down $3.60 on Monday, reaching $199.60. 2,388,352 shares of the company were exchanged, compared to its average volume of 3,495,257. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The company has a market capitalization of $142.85 billion, a price-to-earnings ratio of 38.76, a PEG ratio of 2.85 and a beta of 0.77. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $195.63 and a 200 day moving average of $207.10.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The company had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. On average, equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. Danaher's dividend payout ratio is currently 24.85%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on DHR shares. Guggenheim reiterated a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Evercore ISI decreased their price objective on Danaher from $240.00 to $230.00 and set an "outperform" rating for the company in a research report on Tuesday, April 22nd. TD Cowen boosted their price objective on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research report on Wednesday, April 23rd. The Goldman Sachs Group decreased their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $248.61.

View Our Latest Report on DHR

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines